Tirzepatide, the dual GIP/GLP-1 receptor agonist marketed by Eli Lilly as Mounjaro (for diabetes) and Zepbound (for obesity), has emerged as the first pharmacological therapy to receive regulatory approval for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity—a milestone that could reshape Nordic healthcare economics. The U.S. Food and Drug Administration granted this historic indication to Zepbound in December 2024, following robust Phase 3 SURMOUNT-OSA trial data demonstrating clinically meaningful reductions in apnea-hypopnea index alongside improvements in blood pressure, inflammation markers, and insulin resistance.
For Nordic executives, the implications extend far beyond clinical efficacy. With OSA affecting an estimated 8–10% of Norway’s population and diagnosed prevalence reaching 3.7–4.2% in Finland—figures expected to climb as obesity rates rise—the region faces mounting pressure on sleep clinics and CPAP supply chains. Current first-line therapy, continuous positive airway pressure (CPAP), suffers from notoriously poor long-term adherence; real-world Swedish registry data shows median CPAP usage below therapeutic thresholds in nearly 40% of patients. Tirzepatide’s dual action—simultaneously reducing body weight and improving upper airway mechanics—offers a complementary pathway that could alleviate system bottlenecks.
The Nordic Reimbursement Conundrum
The business calculus becomes particularly acute against the backdrop of Nordic pharmaceutical policy. Despite lacking public reimbursement across Sweden, Norway, and Denmark, Mounjaro has become Sweden’s top-selling pharmacy drug by volume—a testament to extraordinary patient demand and willingness to pay out-of-pocket. Eli Lilly reported combined global sales of Mounjaro and Zepbound reached $36.5 billion in 2025, representing 56% of the company’s $65.2 billion total revenue. Yet Nordic health authorities remain hesitant to fund these therapies at scale, citing budget impact concerns even as untreated OSA drives downstream costs through cardiovascular events, workplace productivity loss, and diabetes complications.
This creates a paradoxical market dynamic: patients self-fund weight-loss medications that may incidentally resolve sleep apnea, while publicly funded CPAP programs struggle with adherence and limited cardiometabolic benefit. The European Medicines Agency has indicated that Mounjaro’s existing EU marketing authorization (granted September 2022) may suffice for OSA treatment without a separate indication—potentially accelerating off-label adoption across Nordic markets. Health technology assessment bodies now face a strategic question: does funding tirzepatide for obesity with documented OSA generate superior cost-effectiveness versus standalone CPAP provision?
Competitive Landscape and Regional Tensions
The narrative gains complexity given Novo Nordisk’s Danish origins and dominant position in the Nordic GLP-1 market with Wegovy and Ozempic. Recent head-to-head SURMOUNT-5 trial data confirmed tirzepatide’s superiority over semaglutide in weight reduction magnitude—a finding that could pressure Novo Nordisk’s regional stronghold. Yet Novo Nordisk faces its own Nordic challenges: Denmark’s Patient Compensation Board recently awarded damages to four patients who developed vision loss linked to semaglutide therapies, creating reputational headwinds in the company’s home market. As both firms race toward next-generation multi-agonists (retatrutide, survodutide), Nordic payers will soon confront even more potent—but costly—therapeutic options.
Forward Look: The Infrastructure Question
The deeper business implication lies not in drug pricing alone but in healthcare infrastructure transformation. If tirzepatide adoption reduces CPAP dependency for even 30% of moderate OSA cases, Nordic countries could redirect capital from device procurement and sleep lab expansions toward metabolic clinics and primary care integration. Conversely, failure to establish reimbursement pathways may exacerbate health inequities, creating a two-tier system where only affluent patients access dual-benefit therapy.
What’s Next?
Our next analysis will examine the budget impact modelling underway at TLV (Sweden), NAS (Norway), and Amgros (Denmark) as these agencies evaluate whether to create OSA-specific reimbursement criteria for GLP-1/GIP agonists. We’ll also assess how Nordic hospital groups are restructuring sleep medicine services in anticipation of pharmacological disruption.
Connect with our healthcare policy team at insights@nordicbusinessjournal.com to share your organisation’s perspective on metabolic-sleep disorder integration—or to request our upcoming Nordic GLP-1 Market Access Briefing.